COREYANN FLUKER: Open Payments
NPI 1467965236 · MONROEVILLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,129 in 247 payments from 27 companies in 2025. Trend: 2023 $4,852 · 2024 $4,097 · 2025 $4,129
Food & beverage: $4,063Education: $66
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 44 | $794 |
| ABBVIE INC. | 36 | $506 |
| Novo Nordisk Inc | 30 | $446 |
| Neurocrine BioSciences, Inc. | 25 | $355 |
| Vanda Pharmaceuticals Inc. | 20 | $272 |
| Teva Pharmaceuticals USA, Inc. | 12 | $262 |
| Janssen Pharmaceuticals, Inc | 11 | $236 |
| Alkermes, Inc. | 9 | $212 |
| E.R. Squibb & Sons, L.L.C. | 9 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $147 |
Products named: REXULTI, VRAYLAR, INGREZZA, ABILIFY ASIMTUFII, Wegovy, INVEGA SUSTENNA, FANAPT, ARISTADA.
Industry payments across PA — which companies pay providers there.
